Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 6 | Journal of Neuroinflammation

Fig. 6

From: The role of microglial P2X7: modulation of cell death and cytokine release

Fig. 6

P2X7 antagonist attenuates BzATP-induced microglial cell death. Microglia were pre-treated with different concentrations of P2X7 antagonist A-804598 for 1 h before exposure to 100 ng/ml LPS for 22 h in the absence or presence of 380 μM BzATP for additional 4.5 h. a Immunocytochemical images of microglia with or without P2X7 antagonist treatment under conditions of BzATP alone, LPS alone, or LPS plus BzATP. White box indicates position of high magnification images shown below. Iba1 as microglial marker shown in red, GFAP as astrocyte marker shown in green, DAPI stains nuclei. Scale bar, 50 μm. b The number of microglia treated by BzATP after pre-treatment with different concentrations of A-804598 quantified by CCK-8 kit. c The number of LPS-primed microglia after pre-treatment with different concentrations of A-804598 in the presence of BzATP quantified by CCK-8 kit. Data are shown as mean + SD. Experiment was done in six replicates and repeated three times independently. Statistical analysis was performed between vehicle- and BzATP-treated groups in b, between LPS- and BzATP-treated groups in c. One-way ANOVA followed by Tukey’s post hoc test. *P < 0.05; ***P < 0.001; ****P < 0.0001

Back to article page